Australian biotech company Acrux has announced plans to export its new testosterone treatment across the globe, following a trial which showed Axiron significantly improved the mood and lifestyle of participants.
“This is a very significant measure for an Australian biotech company,” CEO Richard Treagus told SmartCompany.
“There are only a very small handful of Australian biotech companies that have managed to take a product through all the stages of development to the final stage as we have, so we’re very proud of the results.”
The product’s phase 3 test results, released yesterday, showed Axiron enabled normal testosterone levels in 84% of men after four months of treatment, compared to the 75% required by the US Food and Drug Administration.
After two weeks, 76% of participants had blood testosterone levels within the normal range.
The results place Acrux in a strong position to enter the billion dollar US market for low testosterone and erectile dysfunction treatments.
Acrux will begin a formal partnering process in October, Tragus says. The company hopes to have Axiron on the shelves in Europe, Asia, Australia and North and South America by early 2011.
ABOUT THE AUTHOR
COMMENTS
SmartCompany is committed to hosting lively discussions. Help us keep the conversation useful, interesting and welcoming. We aim to publish comments quickly in the interest of promoting robust conversation, but we’re a small team and we deploy filters to protect against legal risk. Occasionally your comment may be held up while it is being reviewed, but we’re working as fast as we can to keep the conversation rolling.
The SmartCompany comment section is members-only content. Please subscribe to leave a comment.
The SmartCompany comment section is members-only content. Please login to leave a comment.